Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neurooncology Center, Cleveland Clinic, Cleveland, Ohio.
Department of Neurosurgery, University of California Los Angeles, Los Angeles, California.
Neurosurgery. 2018 Sep 1;83(3):345-353. doi: 10.1093/neuros/nyx522.
Guidelines regarding stereotactic radiosurgery (SRS) for brain metastases are missing recently published evidence.
To conduct a systematic review and provide an objective summary of publications regarding SRS in managing patients with 1 to 4 brain metastases.
Using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, a systematic review was conducted using PubMed and Medline up to November 2016. A separate search was conducted for SRS for larger brain metastases.
Twenty-seven prospective studies, critical reviews, meta-analyses, and published consensus guidelines were reviewed. Four key points came from these studies. First, there is no detriment to survival by withholding whole brain radiation (WBRT) in the upfront management of brain metastases with SRS. Second, while SRS on its own provides a high rate of local control (LC), WBRT may provide further increase in LC. Next, WBRT does provide distant brain control with less need for salvage therapy. Finally, the addition of WBRT does affect neurocognitive function and quality of life more than SRS alone. For larger brain metastases, surgical resection should be considered, especially when factoring lower LC with single-session radiosurgery. There is emerging data showing good LC and/or decreased toxicity with multisession radiosurgery.
A number of well-conducted prospective and meta-analyses studies demonstrate good LC, without compromising survival, using SRS alone for patients with a limited number of brain metastases. Some also demonstrated less impact on neurocognitive function with SRS alone. Practice guidelines were developed using these data with International Stereotactic Radiosurgery Society consensus.
立体定向放射外科(SRS)治疗脑转移瘤的指南缺少最近发表的证据。
对 SRS 治疗 1 至 4 个脑转移瘤患者的文献进行系统回顾,提供客观总结。
使用系统评价和荟萃分析的首选报告项目(PRISMA)指南,对 PubMed 和 Medline 截至 2016 年 11 月的文献进行系统检索。另外还对 SRS 治疗较大脑转移瘤进行了检索。
共回顾了 27 项前瞻性研究、综述、荟萃分析和已发表的共识指南。这些研究有以下 4 个关键发现。首先,SRS 作为初始治疗可使患者避免全脑放疗(WBRT),且不会对生存产生不利影响。其次,SRS 本身可提供较高的局部控制率(LC),但 WBRT 可能进一步提高 LC。接下来,WBRT 可提供远处脑控制,减少挽救性治疗的需求。最后,与 SRS 单独治疗相比,WBRT 确实会对神经认知功能和生活质量产生更大影响。对于较大的脑转移瘤,应考虑手术切除,尤其是在单次放疗局部控制率较低的情况下。越来越多的数据表明,多疗程放疗可获得良好的局部控制率和/或降低毒性。
一些精心设计的前瞻性和荟萃分析研究表明,对于脑转移瘤数量有限的患者,单独使用 SRS 可获得良好的局部控制率,且不会影响生存。一些研究还表明,单独使用 SRS 对神经认知功能的影响较小。这些数据以及国际立体定向放射外科协会的共识被用于制定实践指南。